In a phase 2 clinical trial conducted on an obese population, over a 26-week period, patients who were administered a dose range of efinopegdutide from 5 mg to 10 mg experienced a weight reduction of up to 11.8%
This product is not intended for human consumption or veterinary use and is not approved to diagnose, treat, cure, or prevent any disease
The World Anti-Doping Agency (WADA) maintains the Code, as well as the Prohibited List and International Standards
I saw a really interesting talk recently posted on this forum
Practitioners often tailor dose, route, and injection site to the target tissue
Protects Gastric Mucosa: It provides a cytoprotective effect, shielding the stomach lining from the damaging effects of alcohol and NSAIDs